- Home
- RCEL
RCEL
Avita Medical Inc.
as of 12-12-2025 3:43pm EST
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | VALENCIA |
| Market Cap: | 114.3M | IPO Year: | N/A |
| Target Price: | $11.75 | AVG Volume (30 days): | 196.2K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.33 - $14.16 | Next Earning Date: | 11-06-2025 |
| Revenue: | $72,401,000 | Revenue Growth: | 20.59% |
| Revenue Growth (this year): | 13.12% | Revenue Growth (next year): | 27.56% |
AI-Powered RCEL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare RCEL vs Leading Stocks
See how RCEL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RCEL Avita Medical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.